In a phase 3 trial in haemophilia A with or without inhibitors (age 12+), weekly or monthly Mim8 cut estimated mean treated bleeds vs on-demand treatment (0.57 and 0.20 vs 15.76/year); rates were 54.0% and 42.8% lower than in factor prophylaxis run-in. No thromboembolic events.
RCTn = 254
Mancuso et al. Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors